| Nov 17 |
Carisma Therapeutics Presents Promising New Preclinical Data on Engineered Macrophages for the Treatment of Liver Fibrosis at AASLD The Liver Meeting® 2024
|
| Nov 8 |
Carisma Unveils Promising Pre-Clinical Data on Anti-GPC3 In Vivo CAR-M Therapy for Hepatocellular Carcinoma
|
| Nov 7 |
Carisma Therapeutics reports Q3 results
|
| Nov 7 |
Carisma Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights
|
| Nov 5 |
Carisma Therapeutics to Present New Data on Anti-GPC3 In Vivo CAR-M Therapy for Hepatocellular Carcinoma at SITC 2024
|
| Oct 30 |
Carisma Therapeutics Announces Changes to its Board of Directors
|
| Oct 4 |
Carisma Therapeutics Announces Upcoming Presentations at SITC 2024
|
| Sep 10 |
Carisma Therapeutics, Moderna Expand Collaboration Into Autoimmune Diseases
|
| Sep 10 |
Moderna, Carisma deal expands with autoimmune targets
|
| Sep 10 |
Carisma and Moderna Expand Collaboration to Develop Two In Vivo CAR-M Therapies for Autoimmune Diseases
|
